Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a m...
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
About this item
Full title
Author / Creator
Jones, Jeffrey A, MD , Mato, Anthony R, MD , Wierda, William G, Prof , Davids, Matthew S, MD , Choi, Michael, MD , Cheson, Bruce D, Prof , Furman, Richard R, MD , Lamanna, Nicole, MD , Barr, Paul M, MD , Zhou, Lang, PhD , Chyla, Brenda, PhD , Salem, Ahmed Hamed, PhD , Verdugo, Maria, MD , Humerickhouse, Rod A, MD , Potluri, Jalaja, MD , Coutre, Steven, Prof , Woyach, Jennifer, MD and Byrd, John C, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
SummaryBackgroundTherapy targeting Bruton's tyrosine kinase (BTK) with ibrutinib has transformed the treatment of chronic lymphocytic leukaemia. However, patients who are refractory to or relapse after ibrutinib therapy have poor outcomes. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with r...
Alternative Titles
Full title
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Authors, Artists and Contributors
Author / Creator
Mato, Anthony R, MD
Wierda, William G, Prof
Davids, Matthew S, MD
Choi, Michael, MD
Cheson, Bruce D, Prof
Furman, Richard R, MD
Lamanna, Nicole, MD
Barr, Paul M, MD
Zhou, Lang, PhD
Chyla, Brenda, PhD
Salem, Ahmed Hamed, PhD
Verdugo, Maria, MD
Humerickhouse, Rod A, MD
Potluri, Jalaja, MD
Coutre, Steven, Prof
Woyach, Jennifer, MD
Byrd, John C, Prof
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2465717830
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2465717830
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(17)30909-9
